Goldman Sachs Group Inc. Has $490.48 Million Position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Goldman Sachs Group Inc. lessened its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 47.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 3,257,669 shares of the financial services provider’s stock after selling 2,935,453 shares during the period. Goldman Sachs Group Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $490,475,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IBB. Western Wealth Management LLC boosted its stake in shares of iShares Nasdaq Biotechnology ETF by 2.5% in the 4th quarter. Western Wealth Management LLC now owns 2,574 shares of the financial services provider’s stock valued at $390,000 after purchasing an additional 64 shares during the last quarter. Shulman DeMeo Asset Management LLC raised its position in shares of iShares Nasdaq Biotechnology ETF by 0.6% during the 1st quarter. Shulman DeMeo Asset Management LLC now owns 10,123 shares of the financial services provider’s stock valued at $1,524,000 after acquiring an additional 65 shares during the last quarter. Pacific Center for Financial Services lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 7.6% in the 4th quarter. Pacific Center for Financial Services now owns 949 shares of the financial services provider’s stock valued at $144,000 after purchasing an additional 67 shares during the period. Sigma Planning Corp boosted its position in shares of iShares Nasdaq Biotechnology ETF by 0.7% in the 4th quarter. Sigma Planning Corp now owns 9,460 shares of the financial services provider’s stock worth $1,433,000 after purchasing an additional 68 shares during the last quarter. Finally, MinichMacGregor Wealth Management LLC boosted its position in shares of iShares Nasdaq Biotechnology ETF by 3.0% in the 1st quarter. MinichMacGregor Wealth Management LLC now owns 2,743 shares of the financial services provider’s stock worth $412,000 after purchasing an additional 81 shares during the last quarter. 75.58% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ IBB traded down $1.62 on Friday, reaching $161.58. The company had a trading volume of 101,986 shares, compared to its average volume of 3,518,345. iShares Nasdaq Biotechnology ETF has a 52 week low of $125.18 and a 52 week high of $174.04. The company has a 50 day moving average of $151.99.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Market Perform

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.